Progentos Therapeutics
PrivateLast Round
Series A
May 20, 2024
Total Funding Raised
$65M
Company Overview
Progentos Therapeutics is a biotechnology company developing first-in-class small molecule therapeutics designed to regenerate myelin and restore function for patients with multiple sclerosis and other demyelinating diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Progentos Therapeutics Comparables
Compare Progentos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Convelo Therapeutics | 89% | |
| Pheno Therapeutics | 87% | |
| Rewind Therapeutics | 87% | |
Progentos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 20, 2024 |
Progentos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dolby Family Ventures | Series A |
| Forbion | Series A |
| Mission BioCapital | Series A |
| Longwood Fund | Series A |
| Alta Partners | Series A |
Progentos Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Progentos Therapeutics's valuation, stock price, and market status.